- $313.01m
- $324.85m
- $92.13m
- 84
- 39
- 100
- 87
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 24.31 | ||
| PEG Ratio (f) | 0.27 | ||
| EPS Growth (f) | 785.77% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.62 | ||
| Price to Tang. Book | 63.58 | ||
| Price to Free Cashflow | 31.07 | ||
| Price to Sales | 2.99 | ||
| EV to EBITDA | 644.54 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.6% | ||
| Return on Equity | -8.21% | ||
| Operating Margin | -3.68% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 43.31 | 61.29 | 62.45 | 71.52 | 92.13 | 106.51 | 118.13 | 30.23% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +17.25 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OptimizeRx Corporation is a healthcare technology company. The Company’s platform combines artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. Its DAAP generates dynamic audiences with predictive analytics via machine learning methods. MNT creates consumer audiences using a privacy-first process. Its principal solutions include Audience Development: DAAP and MNT, Audience Profiling: Profiler, Audience Activation and Media Execution, Pharmacy Alerts, and Financial Messaging. Its Financial Messaging provides prescribers visibility to branded copay offers for patients directly within their electronic health record (EHR) systems and electronic prescribing (ERx) platforms. Its platform consists of a unified data intelligence technology stack, multiple cloud-based data warehouses, and in-house applications and application programming interface layers.
Directors
- Gus Halas CHM (70)
- William Febbo CEO (52)
- Edward Stelmakh CFO (55)
- Andrew D'silva SVF
- Marion Odence-Ford CCO (56)
- Stephen Silvestro OTH (43)
- James Lang IND (56)
- Patrick Spangler IND (65)
- Lynn Vos IND (65)
- Gregory Wasson IND (62)
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- September 4th, 2008
- Public Since
- May 18th, 2005
- No. of Shareholders
- 274
- No. of Employees
- 106
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
NASDAQ Capital Market- Shares in Issue
- 18,565,033
- Address
- 260 CHARLES STREET, SUITE 302, WALTHAM, 02453
- Web
- https://www.optimizerx.com/
- Phone
- +1 2486516558
- Contact
- Andy Dsilva
- Auditors
- UHY LLP
Upcoming Events for OPRX
Similar to OPRX
180 Life Sciences
NASDAQ Capital Market
36Kr Holdings
NASDAQ Capital Market
3 E Network Technology
NASDAQ Capital Market
A2Z Cust2mate Solutions
NASDAQ Capital Market
Abits
NASDAQ Capital Market
FAQ
What is the OptimizeRx share price?
As of Today at 22:27 UTC, shares in OptimizeRx are trading at $16.86. This share price information is delayed by 15 minutes.
How has the OptimizeRx share price performed this year?
Shares in OptimizeRx last closed at $16.86 and the price had moved by +100.71% over the past 365 days. In terms of relative price strength the OptimizeRx share price has outperformed the S&P500 Index by +72.85% over the past year.
What are the analyst and broker recommendations for OptimizeRx?
The overall consensus recommendation for OptimizeRx is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the OptimizeRx dividend yield?
OptimizeRx does not currently pay a dividend.
Does OptimizeRx pay a dividend?
OptimizeRx does not currently pay a dividend.
When does OptimizeRx next pay dividends?
OptimizeRx does not currently pay a dividend.
How do I buy OptimizeRx shares?
To buy shares in OptimizeRx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of OptimizeRx?
As of the previous close price of $16.86, shares in OptimizeRx had a market capitalisation of $313.01m.
Where are OptimizeRx shares listed?
Here are the trading details for OptimizeRx:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: OPRX
What kind of share is OptimizeRx?
Based on an overall assessment of its quality, value and momentum OptimizeRx is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a OptimizeRx share price forecast for 2025?
The analyst consensus target price for shares in OptimizeRx is $19.00. That is 12.69% above the last closing price of $16.86.
Analysts covering OptimizeRx currently have a consensus Earnings Per Share (EPS) forecast of $0.63 for the next financial year.
Find out moreWhat is the trend in the OptimizeRx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OptimizeRx. Over the past six months, its share price has outperformed the S&P500 Index by +141.31%.
As of the last closing price of $16.86, shares in OptimizeRx were trading +94.34% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the OptimizeRx PE Ratio?
The OptimizeRx PE ratio based on its reported earnings over the past 12 months is 24.31. The shares last closed at $16.86.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of OptimizeRx?
OptimizeRx's management team is headed by:
- Gus Halas - CHM
- William Febbo - CEO
- Edward Stelmakh - CFO
- Andrew D'silva - SVF
- Marion Odence-Ford - CCO
- Stephen Silvestro - OTH
- James Lang - IND
- Patrick Spangler - IND
- Lynn Vos - IND
- Gregory Wasson - IND